Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
Neomorph, Inc
Neomorph, Inc
Bristol-Myers Squibb
City of Hope Medical Center
City of Hope Medical Center
University of Washington
M.D. Anderson Cancer Center
Allogene Therapeutics
NYU Langone Health
University of California, San Francisco
Osel, Inc.
Mabpro, a.s.
Bristol-Myers Squibb
Celldex Therapeutics
Celldex Therapeutics